Transgene says TG4050 posts 100% 3-year disease-free survival in Phase 1 head-and-neck cancer trial

• Transgene reported 3-year follow-up from a Phase 1/2 study of TG4050 in resected, HPV-negative head and neck cancer.
• Phase 1 results were previously shared as a preprint, now published in a peer-reviewed journal.
• Patients who received TG4050 remained in remission with no disease recurrence, supporting its use as an adjuvant monotherapy to prevent relapse.
• The publication backed the proposed immune mechanism, citing durable vaccine-driven T-cell activity against tumor targets.
• Key Phase 2 readouts are scheduled for the second half of 2026, with longer-term recurrence outcomes targeted for Q1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609021200OMX_____CNEWS_FR_GNW1001260669_fr) on September 02, 2026, and is solely responsible for the information contained therein.